Bone Marrow & Stem Cell Transplant

Anne Wooford, MD, provides background on her presentation around allogeneic stem cell transplant for the 2022 Transplantation & Cellular Therapy Meetings.

Pashna Munshi, MD, wraps up by talking about future directions and emerging treatment regimens in the field of GVHD.

A commentary on the patient’s case and strategies for treatment selection and management for those with steroid-refractory disease.

Pashna Munshi, MD, provides an overview of adverse event data from the REACH3 trial of ruxolitinib in patients with steroid-refractory cGVHD and discusses management of patients’ side effects in clinical practice.

A comprehensive review of recent real-world ruxolitinib efficacy data and the use of emerging prognostic markers to risk-stratify patients with cGVHD.

Pashna Munshi, MD, expands upon ruxolitinib’s mechanism of action in steroid-refractory cGVHD and discusses REACH3 efficacy data.

A focused discussion on available treatment options for patients with steroid-refractory cGVHD.

Pashna Munshi, MD reviews risk factors for steroid-refractory cGVHD and the clinical challenges of identification, treatment, and management of the disease.

An overview of common symptoms, diagnostic challenges, and tools for severity assessment of chronic graft-versus-host disease.

Pashna Munshi, MD, discusses the treatment of a 58-year-old man who developed moderate steroid-refractory chronic graft-versus-host disease (cGVHD) after a stem cell transplant, and briefly reviews risk factors for developing cGVHD.

AZALENA trial shows encouraging response rates, duration of response and survival including patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, and acute myeloid leukemia with MDS-related changes.

Ronald L. Paquette, MD, discusses the selection of graft source for bone marrow and stem cell transplants in patients with myelodysplastic syndrome.

Closing out his discussion, Yi-Bin Chen, MD, talks about unmet needs, ongoing clinical trials, emerging treatment options for patients with steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, reflects on the patient case and outlines strategies for educating and managing patients at risk of developing chronic GVHD.

A brief overview of safety and adverse events in the REACH3 trial of ruxolitinib in patients with steroid-refractory chronic GVHD.

A discussion of data from the REACH3 trial and real-world data on the efficacy of ruxolitinib in patients with steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, discusses available treatment options for patients with steroid-refractory chronic GVHD.

Insight on early diagnosis of chronic GVHD and the tools clinicians use to assess GVHD severity.

A comprehensive overview of the symptoms of and organs involved in chronic GVHD.

A focused discussion on various risk factors for developing chronic GVHD and steroid-refractory disease.

Yi-Bin Chen, MD, discusses the work-up, diagnosis, and treatment of a 42-year-old woman with moderate steroid-refractory chronic graft-versus-host disease (GVHD).

Despite its infrequency, early cardiac toxicity may occur more often in patients who received cyclophosphamide-based graft-versus-host disease prophylaxis and those who have a prior history of cardiac disease.

Chimeric antigen receptor T cells manufactured using the Sleeping Beauty transposon in donor-derived cells and differentiated toward the cytokine-induced killer cell protocol induce a sustained response with minimal toxicities in patients with B-cell acute lymphoblastic leukemia.

Lower rates of neutropenia and hypokalemia were also observed with maribavir than valganciclovir, ganciclovir, and foscarnet, and a lower proportion of HCT recipients discontinued treatment with maribavir than IAT.

Haploidentical donor-derived allogeneic hematopoietic cell transplant appears to be feasible for patients with Philadelphia chromosome-positive chronic myeloid leukemia, similar to other donor types.

Ronald L. Paquette, MD, discusses how transplant related morbidity and mortality risks differ between age groups for patients with myelodysplastic syndrome.

In an interview with Targeted Oncology, Ronald Paquette, MD, discussed MDS and what factors may impact the success of a patient’s treatment when undergoing transplant.

Ronald L. Paquette, MD, discusses characteristics of myelodysplastic syndrome and how they may impact a patient’s success in undergoing stem cell transplant.

Results from a retrospective study favor younger matched unrelated donors for consideration in the donor selection for patients with myelodysplastic syndrome.

In the largest study of bone marrow-derived macrophages in post hematopoietic stem cell transplantation patients with a hematologic malignancy, results showed that donor derived cells from the myeloablative transplants accounted for 4.1-25% of microglial cells.